Keros Therapeutics: Business Model, SWOT Analysis, and Competitors 2026

Keros Therapeutics, Inc. stands as a leading company in Healthcare. Generating $244.06 million in annual revenue (growing -87.3% year-over-year) and carrying a market capitalization of $356.76 million, the company has cemented its position as a foundational player in the global Biotechnology landscape. Under the leadership of its leadership team, Keros Therapeutics, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Keros Therapeutics, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Keros Therapeutics, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Keros Therapeutics, Inc.'s position in the Biotechnology market today.

What You Will Learn

1. How Keros Therapeutics, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Keros Therapeutics, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Keros Therapeutics, Inc.'s main competitors are and how the company compares on key financial metrics
4. Keros Therapeutics, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Keros Therapeutics, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $244.06 million annual revenue (TTM), +-87.3% YoY
• Market Cap: $356.76 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 100.0%, operating margin -8355.8%, net margin 35.7%
• Free Cash Flow: $35.67 million
• Return on Equity: 19.9% — strong
• Employees: See latest annual report

Who Owns Keros Therapeutics, Inc.?

Keros Therapeutics, Inc. is publicly traded on the NGM under the ticker symbol KROS. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Keros Therapeutics, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Keros Therapeutics, Inc. has approximately 0.03 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $11.71 per share as of early 2026.

Keros Therapeutics, Inc.'s Mission Statement

Keros Therapeutics, Inc.'s strategic mission is aligned with its core business activities in the Biotechnology sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Keros Therapeutics, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Keros Therapeutics, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Keros Therapeutics, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Keros Therapeutics, Inc. Make Money?

As of 2026, Keros Therapeutics, Inc. generates $244.06 million in annual revenue (growing -87.3% year-over-year), with a 100.0% gross margin and -8355.8% operating margin. Market capitalization stands at $356.76 million. Here is how the company generates its revenue:

Keros differentiates itself through its proprietary platform targeting the TGF-beta superfamily, focusing on diseases with significant unmet medical needs.

What are the key challenges facing Keros Therapeutics?

Key challenges include high research and development costs, regulatory hurdles, and competition from established biotechnology and pharmaceutical companies.

What future opportunities exist for Keros Therapeutics?

Future opportunities include the growing demand for targeted therapies, expanding global markets, and potential partnerships with larger pharmaceutical companies.

How can investors assess Keros Therapeutics?

Investors should analyze Keros' pipeline development, financial health, market positioning, and competitive landscape to assess its potential for growth and investment viability.

By understanding Keros Therapeutics Inc. in detail, stakeholders can make informed decisions regarding engagement with this promising biotechnology company.

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review Keros Therapeutics, Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

Keros Therapeutics, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how Keros Therapeutics, Inc. creates, delivers, and captures value.

Key Partners: Keros Therapeutics, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Biotechnology sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Keros Therapeutics, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Keros Therapeutics, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (N/A employees), proprietary technology, and financial resources ($287.42M in cash).

Value Propositions: Keros Therapeutics, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Biotechnology market.

Customer Relationships: Keros Therapeutics, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Keros Therapeutics, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Keros Therapeutics, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Keros Therapeutics, Inc.'s major costs include cost of goods sold (0.0% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 8455.8% of revenue.

Revenue Streams: Keros Therapeutics, Inc. generates revenue through its core product and service offerings.

Keros Therapeutics, Inc. Competitors

Keros Therapeutics, Inc. competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Biotechnology segment of the Healthcare sector.

Keros Therapeutics, Inc. SWOT Analysis

A SWOT analysis examines Keros Therapeutics, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Keros Therapeutics, Inc.'s gross margin of 100.0% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -8355.8% demonstrates disciplined cost management even at scale.
• Capital Efficiency: A return on equity of 19.9% demonstrates that Keros Therapeutics, Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.

Weaknesses

• Revenue Decline: Year-over-year revenue declined 87.3%, raising questions about demand for Keros Therapeutics, Inc.'s core offerings and requiring management to articulate a credible recovery path.

Opportunities

• Total Addressable Market: Keros Therapeutics, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Keros Therapeutics, Inc.'s products and services.
• Strategic Acquisitions: With $287.42M in cash and strong free cash flow generation, Keros Therapeutics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Keros Therapeutics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Keros Therapeutics, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Keros Therapeutics, Inc. enters 2026 as a leading company in Healthcare, backed by $244.06 million in annual revenue and a 35.7% net profit margin. The company's 100.0% gross margins and $35.67 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Keros Therapeutics, Inc.'s core markets.

For investors, Keros Therapeutics, Inc.'s 7.5x trailing P/E and -2.5x forward P/E reflect the market's expectations for stable earnings. Analysts and investors should watch quarterly earnings releases, management commentary on comparable sales growth, margin trends, and capital allocation for signals of how the investment thesis is progressing.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Keros Therapeutics, SEC EDGAR – Keros Therapeutics Filings, and Keros Therapeutics's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What is Keros Therapeutics Inc. known for?

Keros Therapeutics, Inc. generated $244.06 million in annual revenue with a 35.7% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult Keros Therapeutics, Inc.'s investor relations page.

2. What are the main products in Keros' pipeline?

Keros Therapeutics, Inc. generated $244.06 million in annual revenue with a 35.7% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult Keros Therapeutics, Inc.'s investor relations page.

3. How does Keros Therapeutics differentiate itself from competitors?

Keros Therapeutics, Inc. generates $244.06 million in annual revenue (TTM) with a 100.0% gross margin, growing -87.3% year-over-year. The company's revenue model is described in detail in the business model section above.

4. What are the key challenges facing Keros Therapeutics?

Keros Therapeutics, Inc. faces the following external threats: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Keros Therapeutics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a r Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Keros Therapeutics, Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri Monitoring these risks is essential for investors tracking the company's long-term trajectory.

5. What future opportunities exist for Keros Therapeutics?

Keros Therapeutics, Inc.'s key growth opportunities include: Keros Therapeutics, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this envir Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Keros T With $287.42M in cash and strong free cash flow generation, Keros Therapeutics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reac

6. How can investors assess Keros Therapeutics?

Keros Therapeutics, Inc. generated $244.06 million in annual revenue with a 35.7% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult Keros Therapeutics, Inc.'s investor relations page.